Skip Ribbon Commands
Skip to main content

Efficacy of Low Dose Intravenous Heparin in Preventing Thromboembolism in the SICU

Trial Focus

Trial Focus

Blood Disorders/Diseases, Drugs (Pharmacology), Heart & Circulation


"The heparin study" is comparing the current standard of care for DVT prophylaxis (SQH tid) with a goal-directed IVH infusion (ptt 40-45).
Patients who have consented to participate are randomized upon their postoperative arrival to the SICU to receive heparin SQ or IV per protocol. Bilateral lower extremity ultrasounds are performed on days 0, 5, and 10 to screen for DVTs. Secondary endpoints are PE, sepsis, organ failure, vent days, ICU days, hospital LOS, and 6-month mortality.
We are also looking for changes in blood inflammatory markers, coagulation markers, and markers of endothelial cell damage.

IRB Protocol #


Trial Status

In Progress


Angie Baer RN at 303-266-3230

Eligibility and Other Participant Information

Inclusion Criteria
•admitted to the SICU for initial postoperative care
•18-80 years old
Exclusion Criteria
•currently eligible for treatment of thromboembolism
•already receiving pharmacologic agent for DVT prophylaxis
•initial plt < 30,000
•CP bypass within previous 30 days
•prior organ transplant
•pregnancy, breastfeeding
•prior diagnosis of HIT
•heparin allergy